Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - nimodipine, quantity: 10 mg - injection, intravenous infusion - excipient ingredients: citric acid; sodium citrate dihydrate; water for injections; ethanol; macrogol 400 - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus, e.g., hunt and hess grades i-iii (see section 5.1 pharmacodynamic properties).

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - furosemide, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; sodium chloride - oedema: furosemide ? aft is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. it is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.,furosemide ? aft injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide ? aft is indicated by the intravenous route. parenteral use should be replaced with oral furosemide as soon as practical.

Australia - English - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - 63478 - intraocular scissors, probe-like, single-use - the instruments are sterile, single-use handheld microsurgical tools intended to be used in vitreoretinal surgery for grasping or cutting of intraocular lenses.

United States - English - NLM (National Library of Medicine)

amag pharmaceuticals, inc. - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b) - prasterone 6.5 mg - intrarosa® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. undiagnosed abnormal genital bleeding: any postmenopausal woman with undiagnosed, persistent or recurring genital bleeding should be evaluated to determine the cause of the bleeding before consideration of treatment with intrarosa. risk summary intrarosa is indicated only in postmenopausal women. there are no data with intrarosa use in pregnant women regarding any drug-associated risks. animal reproduction studies have not been conducted with prasterone. risk summary intrarosa is indicated only in postmenopausal women. there is no information on the presence of prasterone in human milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness have not been established in pediatric patients. of the 1522 prasterone-treated postmenopausal women enrolled in the four placebo-controlled 12-week and one open-label 52-week clinical t

United States - English - NLM (National Library of Medicine)

millicent us, inc. - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b) - intrarosa ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. undiagnosed abnormal genital bleeding: any postmenopausal woman with undiagnosed, persistent or recurring genital bleeding should be evaluated to determine the cause of the bleeding before consideration of treatment with intrarosa. risk summary intrarosa is indicated only in postmenopausal women. there are no data with intrarosa use in pregnant women regarding any drug-associated risks. animal reproduction studies have not been conducted with prasterone. risk summary intrarosa is indicated only in postmenopausal women. there is no information on the presence of prasterone in human milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness have not been established in pediatric patients. of the 1522 prasterone-treated postmenopausal women enrolled in the four placebo-controlled 12-week and one open-label 52-week clinic

Philippines - English - FDA (Food And Drug Administration)

alcon laboratories (phils.), inc. - bss (balanced salt solution) sterile intraocular irrigating solution - intraocular irrigating solution - 0.6% + 0.075% + 0.048% + 0.030%

Malta - English - Medicines Authority

gedeon richter plc gyomroi ut 19-21 1103 budapest, hungary - lidocaine - intrauterine liquid gel - lidocaine 42 mg/ml - anesthetics

Ireland - English - HPRA (Health Products Regulatory Authority)

gedeon richter plc - lidocaine - intrauterine gel - 42 milligram(s)/millilitre - lidocaine

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 6 g/l; olive oil, quantity: 24 g/l - injection, intravenous infusion - excipient ingredients: nitrogen; water for injections; sodium hydroxide; egg lecithin; sodium oleate; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methylprednisolone sodium succinate, quantity: 663.13 mg (equivalent: methylprednisolone, qty 500 mg) - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium hydroxide - when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, solu-medrol powder for injection is indicated only for intravenous or intramuscular use in the following conditions:,endocrine disorders,? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).,? acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used).,? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.,? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.,? c